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Introduction
Reduced-intensity conditioning (RIC) regimens allow for
the use of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) in patients with advanced age and/or comorbidi-
ties who are classically not considered eligible for standard
myeloablative allo-HSCT because of a high probability of
non-relapse mortality (NRM). Various RIC regimens with dif-
ferent myeloablative intensities have been described but the
optimal myeloablative intensity is still a matter of debate.1-4
Truly non-myeloablative conditionings (NMAC) are intuitive-
ly preferred in the elderly because of the desirable low NRM.
On the other hand, NMAC may ensure reduced antitumor
activity, resulting in a higher relapse rate, particularly in
patients with advanced or high-risk disease.5 Indeed, we pre-
viously reported that an RIC regimen combining fludarabine
(Flu), intermediate dose of oral busulfan (Bu), and low-dose
rabbit thymoglobulin (r-ATG; Flu-Bu-r-ATG) delivered a bet-
ter antitumor effect than a truly NMAC based on Flu and 2Gy
total body irradiation (TBI). However, the Flu-Bu-r-ATG regi-
men led to an increase in morbidity and mortality, eventually
resulting in similar overall outcomes.3 We later suggested that
the use of intravenous Bu with an intermediate r-ATG dose
could reduce the toxicity of RIC regimens without impairing
disease control.6,7 With this background, we designed a
prospective multicenter phase II trial evaluating the feasibility
and efficacy of an RIC regimen combining Flu, intravenous
Bu, and 5 mg/kg of r-ATG in patients over 55 years of age
with hematologic malignancies.
Methods
Study design
This was a prospective multicenter study. The study protocol was
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Allogeneic transplantation is a challenge in patients of advanced age because of a high risk of non-relapse mortality
and potential long-lasting impairment of health-related quality of life. The development of reduced-intensity con-
ditioning regimens has allowed the use of allogeneic transplantation in this population, but the optimal regimen
remains undefined. We conducted a multicenter phase II trial evaluating the safety and efficacy of a reduced-inten-
sity conditioning regimen combining fludarabine, intravenous busulfan, and rabbit antithymocyte globulins in
patients older than 55 years of age transplanted from matched-related donor. In addition, health-related quality of
life was prospectively measured. Seventy-five patients with a median age of 60 years (range 55-70) were analyzed.
Grade III-IV acute and extensive chronic graft-versus-host diseases were found in 3% and 27% of patients, respec-
tively. The day 100 and 1-year non-relapse mortality incidences were 1% and 9%, respectively. The cumulative
incidences of relapse, progression-free survival and overall survival at two years were 36%, 51% and 67%, respec-
tively, with a median follow up of 49 months. Global health-related quality of life, physical functioning, emotional
functioning, and social functioning were not impaired compared to baseline for more than 75% of the patients
(75%, 81.4%, 82.3%, and 75%, respectively). Thirty-four of the 46 (74%) progression-free patients at one year
were living without persistent extensive chronic graft-versus-host disease. We conclude that the reduced-intensity
conditioning regimen combining fludarabine, intravenous busulfan, and rabbit antithymocyte globulins is well tol-
erated in patients older than 55 years with low non-relapse mortality and long-term preserved quality of life.
(European Union Drug Regulating Authorities Clinical Trials, number 2005-005051-17).
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ABSTRACT
approved by each institutional review board at the eight partici-
pating institutions, the Marseille II Ethical Committee, and the
Cellular Therapy Committee of the French Agency for the Safety
of Health Products. Written informed consent in accordance with
the Declaration of Helsinki was obtained from eligible patients
and their donors prior to inclusion in the study. This trial was reg-
istered with the European Union Drug Regulating Authorities
Clinical Trials, n. 2005-005051-17. Patients aged 55 years or over
presenting with a hematologic malignancy for which an allo-
HSCT was indicated, as previously described,8 were eligible if
they had a matched related donor (MRD). The primary end point
was the 1-year NRM cumulative incidence. Graft-versus-host dis-
ease (GvHD), relapse, progression-free survival (PFS), and overall
survival (OS) were analyzed as secondary end points. Patients
were enrolled in the study between March 2007 and May 2010.
Treatments
Conditioning regimen was a combination of Flu (Fludara;
Schering AG, Lys-Les-Lannoy, France; 30 mg/m² daily on day -5 to
day -1), intravenous Bu (Busilvex; Pierre Fabre, Boulogne-
Billancourt, France; 0.8 mg/kg 4 times daily on days -4 and -3) and
r-ATG (Thymoglobulin; Genzyme, St. Germain-en-Laye, France;
2.5 mg/kg daily, on days -2 and -1). Cyclosporine A, started on day
-3, was used as GvHD prophylaxis. Supportive care, including
anti-infectious drugs and blood product transfusions, was admin-
istered according to the usual policies of each center. Peripheral
blood stem cells (PBSC) were harvested as previously described
with a desired target of 4x106 CD34 cells per kg.3
Health-related quality of life study 
Health-related quality of life (HRQL) was measured prospec-
tively with the European Organization for Research and
Treatment of Cancer Core (EORTC) Quality-of-Life
Questionnaire-C30.9 The transplant patients received the ques-
tionnaire seven days prior to transplantation and on days 80, 180,
and 360 after allo-HSCT. Patients who relapsed were excluded.
Mean arithmetic of EORTC scores from the questionnaires carried
out on day -7 and day +360 were compared using a Wilcoxon rank
sum test. We also compared for each patient the absolute score at
day +360 to the one performed on day -7 before allo-HSCT. We
considered no impairment in HRQL if the absolute EORTC score
at day +360 was at least equal to the one calculated at day -7
before allo-HSCT. As a surrogate marker of HRQL, we analyzed
the prevalence of chronic GvHD (cGvHD) and immunosuppres-
sive treatment (IST) at one year after allo-HSCT in progression-
free patients.
Statistical analyses
To determine the optimal number of patients, a Fleming
method at 1 step was used to detect a maximum NRM incidence
of 25% at one year (considering reduction of 20% compared with
the estimated 45% NRM for standard myeloablative regimens in
this setting). With a P value of 0.01 and an alpha-risk of 90%, 74
patients were needed. Considering that 10% of included patients
may eventually not be evaluable for the main objective, 82
patients were planned. We analyzed the cumulative incidences of
acute GvHD (aGvHD) and cGvHD, as previously described.10,11
We analyzed NRM and relapse using Prentice estimation and the
Gray test, taking into consideration competing events.12,13 Death
without evidence of relapse was considered a competing event for
the incidence of relapse. Similarly, the occurrence of relapse was
considered a competing event for the incidence of NRM while
relapse, progression, and deaths were treated as competing risks
when analyzing the incidence of GvHD. PFS and OS were calcu-
lated using the Kaplan-Meier method, and results were compared
using the log rank test.14 We compared outcome of patients
according to age (<60 vs. >60 years), Karnofsky performance status
(KPS: 90-100 vs. <80), comorbidities using the hematopoietic cell
transplantation comorbidity index (HCT-CI: 0-2 vs. >3),15 and the
refined disease risk index (DRI) (low vs. intermediate vs. high/very
high).16 All survival analyses were computed using R 3.1.0 statisti-
cal software (http://www.R-project.org).
Results
Patients’ and transplant characteristics
Eighty-two patients were included in the study. Seven
patients were excluded because of deviations in terms of
the RIC regimen (n=5), of the donor (n=1), or the investi-
gator’s decision not to proceed to transplant (n=1). Median
age of patients was 60 years; 13 patients were aged 65
years or older (Table 1). Patients were infused with a
median of 4.9x106 CD34-positive cells/kg of body weight
(range 0.7-17). Median follow up was 50 months (range
29-74).
Outcome after allo-HSCT
Overall outcomes after allo-HSCT are described in Table
2. NRM occurred at a median time of nine months (range
2-40) after allo-HSCT for a cumulative incidence of 1% and
9% on days 100 and 365, respectively (Figure 1A). We
found significantly lower 5-year NRM in patients trans-
planted in good performance status (KPS: 90-100: 7% vs.
≤80: 26%; P=0.020) but no difference was observed
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Table 1. Patients’, disease and transplantation characteristics.
                                                                All patients (n=75)
                                                                n                             %
Age (years)                                                                                              
Median [range]                                                 60                             [55-70]
Diagnosis                                                                                                  
AML                                                                    28                                37%
MDS                                                                   14                                19%
MM                                                                     12                                16%
NHL                                                                    11                                15%
CLL                                                                      5                                  7%
ALL                                                                      4                                  5%
CML                                                                    1                                  1%
Disease risk index16                                                                                
Low                                                                     8                                 11%
Intermediate                                                   53                                72%
High                                                                    10                                14%
Very high                                                            2                                  3%
Unknown                                                            2                                     
Karnofsky index                                                                                      
90-100                                                                48                                72%
≤ 80                                                                    19                                28%
Unknown                                                            8                                     
HCT-CI15                                                                                                     
0-2                                                                       26                                36%
=>3                                                                    47                                64%
Unknown                                                            2                                     
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CLL: chronic lym-
phoid leukemia; CML: chronic myeloid leukemia; CR: complete remission; HCT-CI:
hematopoietic cell transplantation comorbidity index; MDS: myelodysplastic syndrome;
MM: multiple myeloma; NHL: non-Hodgkin lymphoma.
according to age and or HCT-CI (Table 3). The cumulative
incidence of grade III-IV aGvHD and extensive cGvHD
were 3% and 27%, respectively, irrespective of age.
Thirty-four patients experienced disease relapse or pro-
gression at a median time of six months (range 1-45) for a
2-year cumulative incidence of 36% (95% confidence
intervals: 25-45) (Figure 1A). Cumulative incidences of
relapse after two years were 0%, 36% and 58% in patients
with low, intermediate and high/very high DRI at the time
of allo-HSCT, respectively (P=0.307). The main cause of
death was disease recurrence (Online Supplementary Table
S1). Two-year PFS and OS probabilities were 51% and
67%, respectively, with no significant differences accord-
ing to age (Figure 1B). We found that DRI significantly pre-
dict PFS and OS (Table 2 and Figure 2).
Patients with acute myeloid leukemia or 
myelodysplastic syndrome in first complete remission 
Twenty-five patients were transplanted for acute
myeloid leukemia (AML) (n=20) or myelodysplastic syn-
drome (MDS) (n=5), both in first complete remission
(CR1). Fourteen (56%) were 60 years or older, 19 (76%)
had an HCT-CI of three or more, and 8 (32%) had poor
cytogenetics. Two-year cumulative incidence of relapse,
PFS, and OS were 20%, 68% and 76%, respectively
(Online Supplementary Figure S1). One year after allo-
HSCT, 20 of 25 (80%) patients were alive and progression
free. Among them, 18 (90%) were free of cGvHD, with-
out IST (n=15) or with tapering IST (n=3). One patient
(5%) was living with treated extensive cGvHD, and one
patient (5%) was living with untreated limited cGvHD.
Health-related quality of life study
One year after allo-HSCT, 46 patients were alive and
disease-free. We received 106 of the expected 184 ques-
tionnaires from these patients (58% reply rate). The
descriptive analysis of the HRQL data revealed that the
lowest functioning scores were experienced one month
after allo-HSCT. Similar results were observed for the
symptom scores. Thereafter, the level of symptoms
decreased and levels of functioning increased and showed
trends toward returning to day -7 before allo-HSCT levels.
Online Supplementary Figure S2 presents results for three
functioning scales (physical functioning, cognitive func-
tioning, and quality of life) and one symptom (fatigue). We
performed a descriptive analysis of patients’ answers
based on patients completing both the first and last self-
report questionnaires (n=16). One year after allo-HSCT,
Quality of life after allo-HSCT for older patients   
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Figure 1. Outcome after allo-hematopoietic stem cell transplantation
(HSCT). (A) Cumulative incidences of non-relapse mortality (NRM)
and relapse (CIR). (B) Progression-free survival (PFS) and overall sur-
vival (OS) estimation.
Figure 2. Outcome according to the revised disease risk index (DRI).
(A) Progression-free survival (PFS). (B) Overall survival (OS). 
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global quality of life, physical functioning, emotional func-
tioning, and social functioning were not impaired com-
pared to day -7 before allo-HSCT for more than 75% of
the patients (75%, 81.4%, 82.3%, and 75%, respectively)
(Figure 3). Role functioning (38.9%) and cognitive func-
tioning (28.8%) were the most impaired with a reduction
in score one year after transplant. With regards to symp-
toms, pain and fatigue one year after transplant were not
impaired for 81.3% and 70.6% of the patients, respective-
ly. Of these 46 patients, 34 (74%) were living without
cGvHD (30 without IST and 4 with tapering IST).
Discussion
We observed that an RIC regimen associating Flu, intra-
venous Bu, and an intermediate dose of r-ATG was well
tolerated in patients 55 years of age or older undergoing
allo-HSCT for hematologic malignancies. Indeed, we
found a very low incidence of early NRM (1%), which is
likely related to both low regimen-related toxicity and low
incidence of severe forms of aGvHD (grade III-IV: 3%). At
a later stage, the incidence of NRM remained low (1-year:
9%; 5-year: 14%) with respect to median age (60 years;
range 55-70) and high comorbidity score (hematopoietic
cell transplantation specific-comorbidity index ≥3: 64%).
This promising safety profile is equivalent to that
observed in patients receiving truly NMAC. Indeed, Storb
et al. recently reported day 100, 1-year, and 5-year inci-
dences of NRM of 4%, 15%, and 21%, respectively, in
patients with a median age of 56 years (range 17-74) pre-
pared with 2 Gy TBI +/− Flu.17 Taken together, these
results show that this Flu–ivBU–ATG regimen delivers
intermediate doses of myeloablation without increasing
toxicity. The 53% OS at five years is also of interest with
regards to the characteristics of the patient population: in
addition to age and comorbidities, only 11% of the
patients were considered to be low risk according to the
refined DRI. The relapse rate remained relatively high
with a 5-year PFS of 39%. However, when focusing only
on the CR1 AML/MDS patients, we found a promising 2-
year OS and PFS of 76% and 68%, respectively, with a
D. Blaise et al.
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Table 2. Outcome after allo-HSCT.  
                                                                  All patients (n=75)
                                                                %                   (95%CI)
Acute GvHD                                                                                           
Grade II-IV                                                         21%                      (12-31)
Grade III-IV                                                        3%                         (0-6)
Chronic GvHD                                                                                       
Limited + Extensive                                       47%                      (35-58)
Extensive                                                           27%                      (17-37)
Non-relapse mortality                                     14%                       (7-23)
Incidence of relapse                                       46%                      (35-58)
Progression-free survival                               39%                      (29-52)
Overall survival                                                  53%                      (42-65)
Follow up (months)                                                                            
Median [range]                                                  49                        [29-74]
Estimations are noted at 5 years except for acute graft-versus-host disease (aGvHD)
that is estimated at day 100.
Table 3. Univariate analyses of non-relapse mortality and overall sur-
vival. 
N NRM P OS P
Age
< 60 years 33 12% 0.650 61% 0.579
≥ 60 years 42 17% 45%
Karnofsky index
90-100 48 7% 0.020 42% 0.146
≤ 80 19 26% 56%
HCT-CI15 
0-2 26 20% 0.514 39% 0.094
≥ 3 47 13% 62%
Disease risk index16
Low 8 13% 0.500 88% 0.041
Intermediate 53 9% 56%
High / Very high 12 25% 31%
HCT-CI: hematopoietic cell transplantation comorbidity index; NRM: non-relapse mortal-
ity; OS: overall survival. Estimations are provided at 5 years. 
Figure 3. The proportion of patients reporting no
impaired EORTC score one year after transplanta-
tion compared with base-line evaluation.  *Score
one year after transplantation is inferior to the day
-7 score (pre-graft score). **Score one year after
transplantation is superior or equal to the day -7
score (pre-graft score).  
low incidence of relapse of 20%. The disease control
achieved in patients with less advanced diseases is of
interest and comparable to that observed with condition-
ings that were more intensive. Alatrash et al. recently
reported 79 AML or MDS patients with a median age of
58 years (range 55-76) undergoing allo-HSCT prepared
with 4-day intravenous Bu.18 When analyzing only the
data from patients transplanted in CR1, they reported a 2-
year OS and PFS of 71% and  68%, respectively, which is
comparable to our results.
In addition to classical transplant outcomes, this clinical
trial prospectively measured the HRQL in disease-free
patients, which is a major issue, and one that is not fre-
quently reported. Only 58% of the patients answered the
HRQL study adequately. This rather low rate may be due
to the age of the patient population studied; older patients
are usually more reluctant to complete self-report ques-
tionnaires than younger patients.19 Due to the small sam-
ple size, one can argue that the statistical analyses used
could not reflect the real population scores. To address this
issue, we chose to perform a descriptive analysis of the
proportion of patients whose EORTC scores returned to
those of day -7 before allo-HSCT. This analysis provided
encouraging results with a majority of patients describing
EORTC scores that improved one year after transplant
when compared to pre-transplantation scores. While poor
quality of life is often presented as a limitation of allo-
HSCT in older patients, our study suggested that, one year
after transplantation, the majority of patients over 55
years of age had recovered standard of health outcomes
similar to those recorded in the pre-transplant period. It is
well known that cGvHD, particularly with refractory
and/or recurrent extensive forms, is the main cause for
changes in HRQL.20,21 In this series, 74% of the disease-
free patients at one year after allo-HSCT were free of per-
sisting cGvHD. The intermediate dose of r-ATG could, in
part, explain these promising results. Indeed, we previous-
ly reported that the dose of r-ATG is critical for outcome
after allo-HSCT, showing that an intermediate dose of 5
mg/kg results in effective GvHD prophylaxis while pre-
serving disease control.22,23 The latter underlies the pivotal
role of in vivo T-cell depletion even in the setting of MRD,
which was recently confirmed in the large European
Group for Blood and Marrow Transplantation study.24
Overall, these results suggest that such RIC regimens
could represent an optimal balance between safety and
efficacy in a population of elderly patients transplanted
from matched related donor. These results may differ
when using unrelated donors. Alousi et al. reported that
unrelated allo-HSCT were associated with higher inci-
dences of GvHD and NRM in patients older than 50 years
of age.25 In line with these data, we previously reported a
1-year NRM of 24% using the similar Flu-Bu-ATG plat-
form in patients over 55 years of age receiving allo-HSCT
from an unrelated donor compared to 9% in this present
series.26 
Advanced diseases remain a major concern. Further
developments to improve the antitumor effect of this Flu–
ivBU–ATG platform are required. In this perspective, mye-
loablative regimens with reduced toxicity conditioning
(MA-RTC) recently appeared as a valuable option in inter-
mediate age patients combining both the low incidences
of NRM from RIC regimens and the high antitumor
effects from MAC.27-29 Furthermore, although in younger
patients standard MAC may still play a role,30-32 MA-RTC
have been reported to be associated with lower incidences
of GvHD and NRM but to a similar relapse rate in compar-
ison to standard Bu plus cyclophosphamide MAC regi-
mens, leading to improved outcomes.33,34 
Previous studies suggested that the dose of intravenous
Bu could be safely increased in elderly patients with the
aim of achieving better disease control in this setting in
which standard MAC regimens are not an option.18 This
hypothesis is currently being addressed in a French multi-
center prospective clinical trial, where patients with high-
risk myeloid malignancies will be randomized to receive
different doses of intravenous Bu (6.4 vs. 9.6 vs. 12.8 mg/kg
total dose). 
In conclusion, we confirm that the current RIC regimen
combining Flu, 2-day intravenous Bu, and 5mg/kg r-ATG
resulted in reduced early toxicity and NRM, and interest-
ing long-term preserved HRQL in elderly patients who
underwent matched related allo-HSCT. 
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